Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
LongevityResearch Phase

Humanin

Subcutaneous injection, Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cytoprotective and neuroprotective effects by interacting with IGFBP-3, BAX, and the FPRL-1 receptor.

Mechanism of Action

It inhibits apoptosis through suppression of the intrinsic mitochondrial death pathway and reduces amyloid-beta-induced neurotoxicity.

Research Summary & Key Findings

Discovered in 2001 as a survival factor against Alzheimer's disease-related neuronal death. Studies show protection against oxidative stress, atherosclerosis, and age-related cognitive decline. Circulating humanin levels inversely correlate with age and Alzheimer's disease progression (Hashimoto et al., PNAS, 2001).

Clinical Status

Research Phase

Humanin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Longevity

No lawful pathway today

Humanin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.